Loading...

Sinovac Biotech

Nasdaq:SVA
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SVA
Nasdaq
$640M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
SVA Share Price and Events
7 Day Returns
0%
NasdaqGS:SVA
1%
US Biotechs
0.2%
US Market
1 Year Returns
-14%
NasdaqGS:SVA
-4.6%
US Biotechs
2.9%
US Market
SVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sinovac Biotech (SVA) 0% 0% 0% -14% 6.4% 2.9%
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • SVA underperformed the Biotechs industry which returned -4.6% over the past year.
  • SVA underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
SVA
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Sinovac Biotech's competitors could be found in our database.

SVA Value

 Is Sinovac Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sinovac Biotech. This is due to cash flow or dividend data being unavailable. The share price is $6.47.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sinovac Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sinovac Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:SVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.34
NasdaqGS:SVA Share Price ** NasdaqGS (2019-02-22) in USD $6.47
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sinovac Biotech.

NasdaqGS:SVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SVA Share Price ÷ EPS (both in USD)

= 6.47 ÷ 0.34

19.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinovac Biotech is good value based on earnings compared to the US Biotechs industry average.
  • Sinovac Biotech is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Sinovac Biotech's expected growth come at a high price?
Raw Data
NasdaqGS:SVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 19.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
24.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sinovac Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sinovac Biotech's assets?
Raw Data
NasdaqGS:SVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.56
NasdaqGS:SVA Share Price * NasdaqGS (2019-02-22) in USD $6.47
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqGS:SVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SVA Share Price ÷ Book Value per Share (both in USD)

= 6.47 ÷ 3.56

1.82x

* Primary Listing of Sinovac Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinovac Biotech is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Sinovac Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sinovac Biotech has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SVA Future Performance

 How is Sinovac Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Sinovac Biotech, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
24.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sinovac Biotech expected to grow at an attractive rate?
  • Sinovac Biotech's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Sinovac Biotech's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Sinovac Biotech's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:SVA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:SVA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 24.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:SVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:SVA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 230 8 22
2018-09-30 230 26 25
2018-06-30 230 45 29
2018-03-31 202 53 27
2017-12-31 174 60 26
2017-09-30 152 34 23
2017-06-30 127 5 19
2017-03-31 95 -3 4
2016-12-31 72 -14 -3
2016-09-30 64 -2 -7
2016-06-30 52 -5 -11
2016-03-31 69 1 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sinovac Biotech's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Sinovac Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:SVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sinovac Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SVA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.34
2018-09-30 0.42
2018-06-30 0.50
2018-03-31 0.48
2017-12-31 0.45
2017-09-30 0.40
2017-06-30 0.32
2017-03-31 0.06
2016-12-31 -0.05
2016-09-30 -0.12
2016-06-30 -0.20
2016-03-31 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sinovac Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sinovac Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sinovac Biotech has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SVA Past Performance

  How has Sinovac Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sinovac Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sinovac Biotech has delivered over 20% year on year earnings growth in the past 5 years.
  • Sinovac Biotech's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Sinovac Biotech's 1-year earnings growth is negative, it can't be compared to the US Biotechs industry average.
Earnings and Revenue History
Sinovac Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sinovac Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SVA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 229.65 21.78 137.82 21.91
2018-09-30 229.79 25.41 129.64 21.85
2018-06-30 229.93 29.04 121.46 21.78
2018-03-31 202.14 27.42 104.88 21.14
2017-12-31 174.35 25.81 88.30 20.49
2017-09-30 151.99 22.78 78.37 18.21
2017-06-30 127.01 18.51 65.61 16.58
2017-03-31 94.93 3.52 55.57 14.97
2016-12-31 72.43 -2.93 43.39 12.65
2016-09-30 64.02 -6.77 38.91 11.93
2016-06-30 52.05 -11.39 36.51 9.93
2016-03-31 69.16 0.68 37.12 9.36
2015-12-31 67.41 -0.69 37.43 9.49
2015-09-30 64.61 1.87 35.38 10.05
2015-06-30 65.24 1.41 34.62 10.50
2015-03-31 58.59 -1.39 33.26 11.43
2014-12-31 62.93 0.01 34.67 10.93
2014-09-30 65.73 3.67 33.04 9.97
2014-06-30 70.66 5.89 33.93 9.46
2014-03-31 76.02 9.46 34.57 8.24
2013-12-31 71.77 8.71 33.11 8.13
2013-09-30 69.17 -2.99 39.84 7.17
2013-06-30 61.38 -8.30 35.30 8.91
2013-03-31 53.29 -11.25 35.50 11.55
2012-12-31 49.22 -14.85 32.41 17.04
2012-09-30 50.77 -7.48 23.21 18.05
2012-06-30 51.84 -5.91 24.14 16.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Sinovac Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Sinovac Biotech used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.
  • Sinovac Biotech has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Sinovac Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sinovac Biotech has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SVA Health

 How is Sinovac Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sinovac Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sinovac Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sinovac Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sinovac Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 20.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sinovac Biotech Company Filings, last reported 4 months ago.

NasdaqGS:SVA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 291.93 13.92 177.08
2018-09-30 291.93 13.92 177.08
2018-06-30 197.13 29.45 88.11
2018-03-31 197.13 29.45 88.11
2017-12-31 177.14 40.07 114.42
2017-09-30 177.14 40.07 114.42
2017-06-30 149.55 36.51 54.98
2017-03-31 149.55 36.51 54.98
2016-12-31 129.67 43.03 62.43
2016-09-30 127.60 37.79 54.32
2016-06-30 123.42 29.18 49.22
2016-03-31 138.39 35.95 62.51
2015-12-31 136.51 25.00 63.83
2015-09-30 138.78 28.25 54.36
2015-06-30 143.22 35.24 64.76
2015-03-31 139.33 33.14 63.07
2014-12-31 141.73 51.77 91.29
2014-09-30 140.28 58.93 94.35
2014-06-30 139.13 50.87 89.63
2014-03-31 142.22 53.58 101.65
2013-12-31 143.64 51.69 107.24
2013-09-30 134.42 48.84 89.03
2013-06-30 130.90 48.92 92.05
2013-03-31 127.56 45.21 91.56
2012-12-31 129.44 37.74 91.24
2012-09-30 134.38 29.44 81.96
2012-06-30 137.19 28.05 89.44
  • Sinovac Biotech's level of debt (4.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (36% vs 4.8% today).
  • Debt is well covered by operating cash flow (57.1%, greater than 20% of total debt).
  • Sinovac Biotech earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Sinovac Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sinovac Biotech has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SVA Dividends

 What is Sinovac Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sinovac Biotech dividends.
If you bought $2,000 of Sinovac Biotech shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sinovac Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sinovac Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:SVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sinovac Biotech has not reported any payouts.
  • Unable to verify if Sinovac Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sinovac Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sinovac Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sinovac Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sinovac Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sinovac Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SVA Management

 What is the CEO of Sinovac Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Weidong Yin
COMPENSATION $0
AGE 53
TENURE AS CEO 15.7 years
CEO Bio

Dr. Weidong Yin has been the Chief Executive Officer, President and Secretary at Sinovac Biotech Ltd. since September 24, 2003 and served as its Managing Director. Dr. Yin serves as General Manager of Sinovac Biotech Co. Ltd. He serves as the President at Sinovac Biotech Co., Ltd. He is responsible for the State Model Project for Hi-tech Industrialization. He served as General Manager of Tangshan Yian Bioengineering Co., Ltd and served as a Medical Doctor in infectious disease at the China Center for Disease Control and Prevention, Tangshan City, Hebei Province. He served as the Chief Executive Officer, President and Secretary at Net Force Systems Inc. since September 24, 2003. He has devoted 20 years to the Hepatitis A virus research and is the technological inventor of Inactive Hepatitis A Vaccine. Dr. Yin is also heading the research on Inactivated SARS Vaccine. In addition, he was appointed to be the principal investigator by the Chinese Ministry of Science and Technology for many key governmental R&D programs such as 'Inactivated Hepatitis A vaccine R&D', 'Inactivated SARS vaccine R&D' and 'New Human Influenza Vaccine (H5N1) R&D'. He serves as the Chairman of the Board at Sinovac Hong Kong, Tangshan Yian and Sinovac Dalian. He served as Chairman of the Board at Sinovac Biotech Ltd. and serves as its Director since September 24, 2003. Dr. Yin serves as Director of Sinovac Biotech Co. He served as a Director at Net Force Systems Inc. since September 24, 2003. He obtained his Master’s degree in Business Administration from the Singapore State University. He obtained his MBA from the National University of Singapore and his medical degree from Tangshan Medical School.

CEO Compensation
  • Insufficient data for Weidong to compare compensation growth.
  • Weidong's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Sinovac Biotech management team in years:

8.3
Average Tenure
52
Average Age
  • The average tenure for the Sinovac Biotech management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Weidong Yin

TITLE
Chairman
AGE
53
TENURE
15.7 yrs

Nan Wang

TITLE
CFO & VP of Business Development
AGE
52
TENURE
5.9 yrs

Ming Xia

TITLE
Vice President of Sales & Marketing
AGE
44
TENURE
8.3 yrs
Board of Directors Tenure

Average tenure and age of the Sinovac Biotech board of directors in years:

13.2
Average Tenure
55
Average Age
  • The average tenure for the Sinovac Biotech board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Weidong Yin

TITLE
Chairman
AGE
53
TENURE
15.7 yrs

Simon Anderson

TITLE
Independent Director
AGE
57
TENURE
14.8 yrs

Yuk Lo

TITLE
Independent Director
AGE
69
TENURE
13.2 yrs

Meng Mei

TITLE
Independent Director
AGE
63
TENURE
7.2 yrs

Jian Lee

TITLE
Independent Director
AGE
50
TENURE
8 yrs

Shan Fu

TITLE
Independent Director
AGE
49
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Aug 18 Buy Vivo Capital, LLC Company 24. Aug 18 24. Aug 18 4,539,456 $7.35 $33,365,002
27. Aug 18 Sell Vivo Capital, LLC Company 24. Aug 18 24. Aug 18 -4,539,456 $7.35 $-33,365,002
20. Jul 18 Buy Vivo Capital, LLC Company 19. Jul 18 19. Jul 18 1,360,544 $7.35 $9,999,998
20. Jul 18 Sell Vivo Capital, LLC Company 19. Jul 18 19. Jul 18 -1,360,544 $7.35 $-9,999,998
11. Jul 18 Buy Vivo Capital, LLC Company 02. Jul 18 02. Jul 18 5,900,000 $7.35 $43,365,000
X
Management checks
We assess Sinovac Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sinovac Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SVA News

Simply Wall St News

How Good Is Sinovac Biotech Ltd (NASDAQ:SVA), When It Comes To ROE?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.21 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

A Holistic Look At Sinovac Biotech Ltd (NASDAQ:SVA)

I've been keeping an eye on Sinovac Biotech Ltd (NASDAQ:SVA) because I'm attracted to its fundamentals. … is a company that has been able to sustain great financial health, trading at an attractive share price. … report on Sinovac Biotech here

Simply Wall St -

Does Sinovac Biotech Ltd's (NASDAQ:SVA) PE Ratio Warrant A Buy?

By comparing a stock’s price per share to its earnings per share, we are able to see how much investors are paying for each dollar of the company’s earnings. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for SVA Price per share = $7.82 Earnings per share = $0.452 ∴ Price-Earnings Ratio = $7.82 ÷ $0.452 = 17.3x The P/E ratio itself doesn’t tell you a lot; however, it becomes very insightful when you compare it with other similar companies. … SVA’s P/E of 17.3x is lower than its industry peers (25.8x), which implies that each dollar of SVA’s earnings is being undervalued by investors.

Simply Wall St -

How Sinovac Biotech Ltd (NASDAQ:SVA) Delivered A Better ROE Than Its Industry

See our latest analysis for Sinovac Biotech Breaking down ROE — the mother of all ratios Return on Equity (ROE) is a measure of Sinovac Biotech’s profit relative to its shareholders’ equity. … This means Sinovac Biotech returns enough to cover its own cost of equity, with a buffer of 9.65%. … Sinovac Biotech exhibits a strong ROE against its peers, as well as sufficient returns to cover its cost of equity.

Simply Wall St -

What Kind Of Risk Should You Expect For Sinovac Biotech Ltd (NASDAQ:SVA)?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … See our latest analysis for Sinovac Biotech An interpretation of SVA's beta Sinovac Biotech's beta of 0.1 indicates that the stock value will be less variable compared to the whole stock market. … SVA's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns.

Simply Wall St -

Who Are The Major Shareholders In Sinovac Biotech Ltd (NASDAQ:SVA)?

Check out our latest analysis for Sinovac Biotech NasdaqGS:SVA Ownership_summary Mar 5th 18 Institutional Ownership In SVA's case, institutional ownership stands at 13.25%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … This level of insider ownership has been found to have a negative impact on companies with consistently low PE ratios (underperformers), while it has been positive in the case of high PE ratio firms (outperformers). … Thus, investors should dig deeper into SVA's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: SVA's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Future Outlook Of The Healthcare Industry And Sinovac Biotech Ltd (NASDAQ:SVA)

In this article, I’ll take you through the sector growth expectations, as well as evaluate whether Sinovac Biotech is lagging or leading its competitors in the industry. … Given the lack of analyst consensus in Sinovac Biotech’s outlook, we could potentially assume the stock’s growth rate broadly follows its biotech industry peers. … NasdaqGS:SVA PE PEG Gauge Jan 23rd 18 The biotech industry is trading at a PE ratio of 27x, higher than the rest of the US stock market PE of 20.1x.

Simply Wall St -

Should You Be Tempted To Buy Sinovac Biotech Ltd (NASDAQ:SVA) At Its Current PE Ratio?

Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for SVA Price per share = $7.99 Earnings per share = $0.325 ∴ Price-Earnings Ratio = $7.99 ÷ $0.325 = 24.6x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … SVA’s P/E of 24.6x is lower than its industry peers (29.5x), which implies that each dollar of SVA’s earnings is being undervalued by investors. … For example, if you are inadvertently comparing lower risk firms with SVA, then SVA’s P/E would naturally be lower than its peers, since investors would value those with lower risk with a higher price.

Simply Wall St -

Can Sinovac Biotech Ltd (SVA) Continue To Outperform Its Industry?

Check out our latest analysis for Sinovac Biotech Breaking down ROE — the mother of all ratios Return on Equity (ROE) is a measure of SVA’s profit relative to its shareholders’ equity. … Since SVA’s return covers its cost in excess of 8.01%, its use of equity capital is efficient and likely to be sustainable. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity NasdaqGS:SVA Last Perf Dec 8th 17 Basically, profit margin measures how much of revenue trickles down into earnings which illustrates how efficient SVA is with its cost management.

Simply Wall St -

What You Must Know About Sinovac Biotech Ltd's (SVA) Major Investors

Therefore, it is beneficial for us to examine SVA's ownership structure in more detail. … See our latest analysis for SVA NasdaqGS:SVA Ownership_summary Nov 29th 17 Institutional Ownership In SVA's case, institutional ownership stands at 13.29%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … Although this doesn't necessarily lead to high short-term volatility, we should dig deeper into SVA's ownership structure to find how the remaining owner types can affect its investment profile.

Simply Wall St -

SVA Company Info

Description

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company’s product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella and pneumococcal polysaccharide vaccines. In addition, it has completed Phase I/II clinical trials for Sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate vaccine, rubella vaccine, and quadrivalent influenza vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; and Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

Details
Name: Sinovac Biotech Ltd.
SVA
Exchange: NasdaqGS
Founded: 1999
$640,001,032
98,918,243
Website: http://www.sinovacbio.com
Address: Sinovac Biotech Ltd.
No. 15 Zhi Tong Road,
Zhongguancun Science & Technology Park,
Beijing,
102200,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SVA Common Stock Nasdaq Global Select US USD 28. Oct 2003
DB SVQ Common Stock Deutsche Boerse AG DE EUR 28. Oct 2003
Number of employees
Current staff
Staff numbers
735
Sinovac Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 04:39
End of day share price update: 2019/02/22 00:00
Last earnings filing: 2019/04/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.